Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.74 |
| ▸ | NPC1 | O15118 | 11/20 | 0.74 |
| ▸ | MAPT | P10636 | 9/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.74 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.74 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.58 |
| ▸ | RELA | Q04206 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | TPH1 | P17752 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20968228 | 0.95 | RAB9A (0.68) | RAB9ANPC1MAPTSMN1; SMN2NR1H4 | |
| SCHEMBL17831085 | 0.87 | KMT2A (0.62) | RAB9ANPC1MAPTSMN1; SMN2NR1H4 | |
| SCHEMBL6697420 | 0.85 | NR1H4 (1.00) | RAB9ANPC1MAPTSMN1; SMN2NR1H4 | |
| SCHEMBL7291752 | 0.85 | NR1H4 (1.00) | RAB9ANPC1MAPTSMN1; SMN2NR1H4 | |
| SCHEMBL12895918 | 0.85 | RAB9A (0.76) | RAB9ANPC1MAPTSMN1; SMN2NR1H4 | |
| SCHEMBL3057492 | 0.84 | RAB9A (0.74) | RAB9ANPC1MAPTSMN1; SMN2NR1H4 | |
| SCHEMBL26095707 | 0.84 | RAB9A (1.00) | RAB9ANPC1MAPTSMN1; SMN2NR1H4 | |
| SCHEMBL29936657 | 0.84 | RAB9A (0.74) | RAB9ANPC1MAPTSMN1; SMN2NR1H4 | |
| SCHEMBL16592531 | 0.84 | RAB9A (0.74) | RAB9ANPC1MAPTSMN1; SMN2NR1H4 | |
| SCHEMBL13416230 | 0.84 | NPC1 (1.00) | RAB9ANPC1MAPTSMN1; SMN2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168062-B2 | Compounds for the treatment of Clostridium difficile infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210340117-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-11-04 | — | — | US | disclosed |
| US-20210340116-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-11-04 | — | — | US | disclosed |
| US-20190210984-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2019-07-11 | — | — | US | disclosed |
| US-9045442-B2 | Antibacterial compounds and methods of using same | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045442-B2 | Antibacterial compounds and methods of using same | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045442-B2 | Antibacterial compounds and methods of using same | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2015-06-02 | — | — | US | disclosed |
| US-20100261673-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261673-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261673-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2009082398-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009082398-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009041972-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009041972-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210984-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | VNN1, NGLY1, NUCB2 | RAB9A 4715/4885NPC1 1749/4885MAPT 2752/4885 |
| US-11168062-B2 | Compounds for the treatment of Clostridium difficile infection | VNN1, NGLY1, NUCB2 | RAB9A 4715/4885NPC1 1749/4885MAPT 2752/4885 |
| US-20210340117-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | VNN1, NGLY1, NUCB2 | RAB9A 4715/4885NPC1 1749/4885MAPT 2752/4885 |
| US-20210340116-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | VNN1, NGLY1, NUCB2 | RAB9A 4715/4885NPC1 1749/4885MAPT 2752/4885 |
| US-20100261673-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME | SPOUT1, MRPL21, NPEPPS | RAB9A 3902/4885NPC1 4451/4885MAPT 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.